Cheng Yi Chen

Title: Cheng Yi Chen: Innovator in Pharmaceutical Chemistry

Introduction

Cheng Yi Chen is a prominent inventor based in San Diego, California. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of KRas G12C inhibitors. With a total of four patents to his name, Chen's work is at the forefront of innovative drug development.

Latest Patents

Chen's latest patents focus on crystalline forms of a KRas G12C inhibitor. The present invention relates to crystalline forms of the KRas G12C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. These patents also cover pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms, and methods of use thereof.

Career Highlights

Throughout his career, Cheng Yi Chen has worked with notable companies in the pharmaceutical industry. He has been associated with Janssen Pharmaceutica and Mirati Therapeutics, where he has contributed to groundbreaking research and development efforts.

Collaborations

Some of Chen's coworkers include Patricia Andres and Samuel Andrew. Their collaborative efforts have further advanced the research and development of innovative pharmaceutical solutions.

Conclusion

Cheng Yi Chen's contributions to the field of pharmaceutical chemistry, particularly through his patents on KRas G12C inhibitors, highlight his role as a leading inventor. His work continues to influence the development of new therapeutic options in the medical field.